PhaseBio Pharmaceuticals (PHAS) Stock Analysis

What PhaseBio Pharmaceuticals does

PhaseBio Pharmaceuticals, Inc. (PHAS) is a clinical-stage biopharmaceutical entity primarily dedicated to discovering, developing, and bringing to market innovative therapies for cardiovascular conditions. Its flagship product in development, bentracimab (PB2452), serves as a reversal agent specifically designed to counteract the effects of the antiplatelet medication ticagrelor. This drug is presently in Phase III clinical trials, targeting patients who are experiencing severe, uncontrolled, or life-threatening bleeding events, or those requiring immediate surgical or invasive interventions. The company's pipeline also features PB1046, a vasoactive intestinal peptide analogue under investigation for pulmonary arterial hypertension, and PB6440, being developed for the management of resistant hypertension. PhaseBio has a strategic co-development alliance with SFJ Pharmaceuticals X, Ltd. for PB2452. Established in 2002 and situated in Malvern, Pennsylvania, PhaseBio Pharmaceuticals, Inc. initiated voluntary reorganization proceedings under Chapter 11 bankruptcy on October 23, 2022, in the U.S. Bankruptcy Court for the District of Delaware.

Key metrics

ETFs linked to PHAS

Broad-market and Healthcare sector ETFs an investor holding PhaseBio Pharmaceuticals is often also exposed to. Open an ETF page to see its actual top holdings.

PortView Portfolio Insights

PortView analyzes how PHAS fits your actual portfolio — position weight, portfolio concentration, unrealized gain/loss, contribution to return, sector exposure, indirect exposure through the ETFs you hold, and correlation with your other holdings. Connect a portfolio to see your personalized figures; PortView never shows another user's private holdings.

Similar companies

Frequently asked questions

What is the ticker symbol for PhaseBio Pharmaceuticals?

PhaseBio Pharmaceuticals trades under the ticker PHAS on NASDAQ.

Which exchange is PHAS listed on?

PHAS is listed on NASDAQ.

What sector does PhaseBio Pharmaceuticals operate in?

PhaseBio Pharmaceuticals is classified in the Healthcare sector (Biotechnology industry).

How can PortView help analyze PHAS in a portfolio?

PortView shows PHAS's weight in your portfolio, its contribution to return and risk, sector exposure, indirect exposure through ETFs you own, and correlation with your other holdings.